http://biotechbistro.com/forum/ The Business of Biotechnology en-US Mon, 06 Feb 2012 09:17:59 +0000 bbpress 1.0-alpha-4 q http://biotechbistro.com/forum/search.php http://biotechbistro.com/forum/topic/where-to-find-cheap-gucci-earrings-and-bracelet#post-436 Fri, 03 Feb 2012 22:50:31 +0000 ringying 436@http://biotechbistro.com/forum/ <p>‘Accessories’ is a very misguiding term when it comes to fashion. Sometimes, the punch added to the fashion statement by some accessories is enough to set the wearer apart from the rest. Not only do they display the fashion taste of a person but also enhance the effect of the dress worn.<br /> <a href="http://www.jewellerygucciuk.com">gucci jewellery</a><br /> The most obvious answer to the above question is the internet. All one needs to do is enter a search keyword related to the above topic and a list of tens of online stores will be displayed who will be offering Gucci bracelet. It is a needless mention that it is hard to resist the temptation of a Gucci bracelet once it has been chosen.<br /> Gucci as a brand name has a lot to speak in itself and this has been proven by the great quality and attractive bracelets that have rolled out from the French Fashion Giant. Gucci Bracelet is ideal for party or a ball. There are a number of designs available and each makes a statement on their own. Depending upon the age and personality, there are various colors and designs to choose from. Besides this, there are ample number of options in terms of weight and detail of the design. The range of Bracelet will take care of all the occasions like ball, marriage, party etc. <a href="http://www.jewellerygucciuk.com">gucci jewellery uk sale</a><br /> A Gucci bracelet for women is an ideal choice for gift and Gucci bracelets almost fit in with all kind of apparel adding to the overall style and charm of one's personality. The collection of Bracelets for men is not limited either. A great number of options are available and it is sure that men of all the body types, personality and taste will have at least a few they would want to buy.<br /> Diamond Earrings are another hot accessory that can leave the people spell bound by its grace and style. The Diamond designs are inspired from real life and this is the reason that they strike the chord of hearts so easily. The Diamond Earrings tell a lot about the craftsmanship and knowledge of style that the brand possesses. Diamond earrings can be bought really cheap now. Looking at the response of the customers worldwide, Diamond adds on very beautiful and cheap accessories to its basket.<br /> <a href="http://www.jewellerygucciuk.com">gucci jewellery sale</a> online stores are a great way of finding the best that comes out from the house of Gucci along with the price, designs, reviews and the discount offers available on various items.<br /> Fraserhart is an online jewelry shop in Glasgow, Uk. To find best and affordable <a href="http://www.jewellerygucciuk.com">gucci jewellery uk</a>, browse fraserhart.co.uk. Here you can select more verity of jewelry as your desire at very affordable price. </p> http://biotechbistro.com/forum/topic/celerion-first-early-stage-contract-research-organization-to-adopt-a-participant#post-434 Thu, 02 Feb 2012 08:03:58 +0000 chelsea.scorr 434@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>MEDIA CONTACTS:<br /> Farzana Azam<br /> Senior Director, Global Marketing<br /> Celerion<br /> +1 (647) 261 3628<br /> <a href="mailto:media.inquiries@celerion.com">media.inquiries@celerion.com</a></p> <p>Kerri Weingard, ANP<br /> Chief Operating Officer<br /> Verified Clinical Trials<br /> +1 516 998-7499<br /> <a href="mailto:KWeingard@verifiedclinicaltrials.com">KWeingard@verifiedclinicaltrials.com</a></p> <p>Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality.</p> <p>(Lincoln, NE; Feb 02, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce it has implemented VCT Verify™ from Verified Clinical Trials, to instantaneously ensure accurate participant identification and qualification for clinical research. Celerion is the first Early Stage Contract Research Organization (CRO) to partner with Verified Clinical Trials to set the standard for the industry to adopt. </p> <p>Celerion will more effectively screen and select higher quality study participants by using this tool to instantly identify ineligible candidates for enrollment. The system searches a global clinical database registry to identify participants that are currently enrolled in other clinical studies. Clients benefit from improved participant selection and higher data integrity.</p> <p>Celerion chose to implement the VCT Verify™ product across all our global clinical facilities to solve the long recognized problem of inaccurate applications that compromise study success. The system has been reviewed and applauded by numerous Institutional Review Boards (IRBs) and Verified Clinical Trials is safe harbor certified.</p> <p>“Celerion continues to apply rigorous standards to protect the safety of participants and enhance data integrity while supporting our commitment to our clients. This implementation sets a standard in the industry to continue to improve clinical research and more effectively bring new drugs to the market,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “We are excited to partner with Verified Clinical Trials, the leader in this specialized field, to take a firm stance on ensuring the highest quality data and participants for our clients.”</p> <p> “Verified Clinical Trials offers a comprehensive and unique clinical research database registry to enhance the quality of both early and late stage studies globally. The system has been designed to streamline the clinical trial process and offers protection from various other potential liabilities,” said Mitchell Efros, MD FACS, CEO at Verified Clinical Trials. “We are pleased to be working with Celerion, the first CRO to implement this product, as they continue to demonstrate their leadership position in the industry.”</p> <p>About Celerion<br /> Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to global clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, global bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit <a href="http://www.celerion.com" rel="nofollow">http://www.celerion.com</a>.</p> <p>About Verified Clinical Trials<br /> Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials defines itself as the world's leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit <a href="http://www.verifiedclinicaltrials.com" rel="nofollow">http://www.verifiedclinicaltrials.com</a>.</p> <p>### </p> http://biotechbistro.com/forum/topic/theorem-clinical-research-appoints-bollwage-as-vice-president-of-global-regulato#post-429 Tue, 17 Jan 2012 09:36:42 +0000 chelsea.scorr 429@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>CONTACT:<br /> Shawn Clary<br /> Theorem Clinical Research<br /> 484.679.2400<br /> <a href="mailto:shawn.clary@theoremclinical.com">shawn.clary@theoremclinical.com</a> </p> <p>Theorem Clinical Research Appoints Bollwage as Vice President of Global Regulatory Affairs</p> <p>(King of Prussia, PA; January 17, 2012) –Theorem Clinical Research, a full-service contract research organization (CRO) that provides core clinical research and development services, is pleased to announce the appointment of Brian Bollwage, J.D., as Vice President of Global Regulatory Affairs.</p> <p>Bollwage previously served as Director of Global Regulatory Science at Bristol-Myers Squibb and as Executive Director and Regulatory Counsel of Global Regulatory Intelligence at i3 Research. </p> <p>“Brian brings a wealth of global regulatory leadership experience in both the CRO and pharmaceutical industries,” stated Theorem Clinical Research Chief Executive Officer John Potthoff. “I am certain that he will excel in his new role.” </p> <p>Bollwage is a food and drug law expert with published articles in Regulatory Affairs Focus, PharmaVOICE and Applied Clinical Trials, among others. A graduate of Rutgers Law School, he currently serves as an associate professor of food and drug law at Temple University in Philadelphia. Bollwage also holds a Master of Business Administration, specializing in pharmaceutical/chemical studies, and a Master of Science. </p> <p>Established in 1985, Theorem Clinical Research is one of the industry’s leading full-service, contract research organizations (CRO). A global organization with 1,000+ employees located throughout 27 countries, Theorem Clinical Research provides core clinical research and development services including statistics, data management and biostatistics for the pharmaceutical, biotech and medical device industries. Theorem Clinical Research manages complex therapeutic studies with speed, flexibility and attention to detail to drive a high-quality performance. </p> <p>About Theorem Clinical Research<br /> Theorem Clinical Research is one of the industry’s leading full-service, contract research organizations (CRO). Before launching in 2011, Theorem Clinical Research operated for nearly two decades as Omnicare Clinical Research under the Omnicare Inc. parent company. A global organization with 1,000+ employees located throughout 27 countries, Theorem Clinical Research provides core CRO services for Phases I-IV, but with niche business units in the areas of technical services, medical devices and pharmaceutics with speed, flexibility and attention to detail to drive a high-quality performance. For more information, visit <a href="http://www.theoremclinical.com" rel="nofollow">http://www.theoremclinical.com</a>.<br /> ### </p> http://biotechbistro.com/forum/topic/celerion-scientist-proud-recipient-of-scientific-and-technological-achievement-a#post-427 Wed, 11 Jan 2012 08:05:09 +0000 chelsea.scorr 427@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE<br /> MEDIA CONTACT:<br /> Farzana Azam<br /> Senior Director, Global Marketing<br /> +1 (647) 261 3628<br /> <a href="mailto:media.inquiries@celerion.com">media.inquiries@celerion.com</a></p> <p>Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA.</p> <p>(Lincoln, NE; Jan 11, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce Don Graff, PharmD, has received the prestigious Scientific and Technological Achievement Award (STAA) from the United States Environmental Protection Agency (EPA). The award is based on the research Dr. Graff undertook while at the EPA, prior to joining the Clinical Pharmacology Sciences business at Celerion.</p> <p>The body of work submitted for the award examined the findings of epidemiological studies conducted in the US and around the world. These data show that various subsets of the population are at risk to suffer cardiopulmonary events, including death, following episodes of elevated particulate matter (PM) pollution in the air. This work addresses biological plausibility and demonstrates that various size fractions of PM may be responsible for the diverse health effects noted in previous studies.</p> <p>Dr. Graff earned a Doctor of Pharmacy degree and completed a residency in Pharmacy Practice at the University of Nebraska Medical Center. He continued his post-graduate training at the University of North Carolina-Chapel Hill where his research focused on treatment and pathophysiology of heart failure. Upon joining the EPA, his work continued in the cardiopulmonary arena through bench-top and clinical studies assessing the effects of air pollution particulate matter on human health. In his role at Celerion, Dr. Graff has applied his cardiopulmonary expertise to the design and analysis of unique clinical research studies.</p> <p>“We are extremely proud of Dr. Graff, and the work submitted to the EPA. This research is especially relevant as it aligns with Celerion’s key strategic focus in the respiratory therapeutic area and early cardiac services,” said Michelle Combs PhD, Vice President of Clinical Pharmacology Sciences at Celerion. “This award is representative of the depth and breadth of scientific expertise that Celerion’s scientists have and is reflected in the high quality work delivered to our clients.”</p> <p>Celerion has one of the most experienced Clinical Pharmacology Sciences team operating in six global locations in North America and Europe for over 40 years. The team produces more than 200 clinical study reports annually and has developed over 4000 protocols. </p> <p>The mission of the EPA is to protect human health and the environment, and air pollution is a significant area of focus for the National Health and Environmental Effects Research Laboratory (NHEERL) within the EPA’s Office of Research and Development. For over two decades scientists at NHEERL have been conducting clinical studies evaluating the effects of air pollutants in support of the Clean Air Act, leading to the implementation of ozone and PM health advisory systems commonly used throughout the US. In addition, these studies have brought about considerable improvements in air quality and air pollution-related health outcomes.</p> <p>About Celerion<br /> Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit <a href="http://www.celerion.com" rel="nofollow">http://www.celerion.com</a>. </p> http://biotechbistro.com/forum/topic/approaches-to-spot-a-fake-juicy-couture-accessory#post-419 Wed, 04 Jan 2012 00:49:30 +0000 raxto 419@http://biotechbistro.com/forum/ <p><a href="http://www.juicycouturejewelryshop.com/">Juicy couture jewelry</a> premiered in 2006 and was an instant success, specifically with younger females.Just before you come to a decision whether or not you like Juicy Couture for by yourself, you will want to try out it on. You may go for your nearest department store and use a tester to put a little of your fragrance on your wrist. Perfume creates a exceptional scent for each and every girl because it reacts for the body chemistry. You might 1st catch the scent of the top note within the perfume, that only lasts several minutes. The mid note will final a bit longer as well as the base note is what tends to attain to your physique chemistry. It is a fantastic strategy for you to stroll close to to get a although after which sniff your arm to find out in the event the perfume agrees with you.</p> <p>There are plenty of variations amongst juicy jewelry and ordinary perfume. These variations encompass every single newer perfumes that have recently been introduced readily available out there and older perfumes. With regard to the newer perfume labels, Juicy Couture is newer for the cause that it doesn't element a celebrity endorsement. Juicy Couture is distinctive than other perfumes on the market that typically are marketed towards either casual or evening wear. Perfume scent is substantially like clothing as well as makeup for the extent that it could be ordinarily reserved for causal or formal occasions.</p> <p>Not like other perfumes,juicy couture jewelry sale is distinctive as it definitely is suitable for the two evening and daytime wear. A lady can really feel absolutely free of charge to wear it whilst out for lunch just as she would if she was to go out to a formal occasion inside the evening.Like other perfumes, Juicy Couture is on the market in pure perfume type, which is essentially the most concentrated in the scent, also as being a wide range of different sprays, creams and gels. Many girls, who just want a hint of fragrance for the day will shower applying bath gel. This may be ordinarily adequate to give you the scent which will linger throughout the day with no being overpowering.</p> <p>Soon after you may have determined which you like juicy couture jewelry outlet and would like to buy it for by yourself, you will need to think about going on the internet and checking out discount perfume homes. It can be possible to generally obtain a significantly improved offer, as substantially as being a 50 percent cost savings, by obtaining perfume on line. It might be generally an incredible plan to save funds and now, far more than ever before, lots of people are looking to reduce back. one way which you can do so is usually to get perfume like Juicy Couture Handbags, on-line.When obtaining Juicy Couture,consider the Body Mist or Physique Sorbet. These are a less concentrated edition within the fragrance and might be applied a great deal far more liberally than the perfume. You are able to also use entire body cream, that's specially well known within the summer season months as this can offer you a soft scent. Moreover, it's possible you'll also use the shower gel every time you shower within the morning to provide your self a hint within the fragrance that may last throughout the day <a href="http://www.juicycouturejewelryshop.com/">juicy jewelry</a>. </p> http://biotechbistro.com/forum/topic/pandora-uk#post-417 Wed, 04 Jan 2012 00:33:08 +0000 raxto 417@http://biotechbistro.com/forum/ <p><a href="http://www.pandoraukonline.net/">Pandora beads uk</a>,When you will have determined you intend to acquire a bracelet in the <a href="http://www.pandoraukonline.net/">pandora charms uk</a> selection, you might rapidly figure out you can find really various a lot far more selections that may will need staying designed. The major some may perhaps be just what measurement Pandora Bracelet should i acquire? Nicely, that is determined by reasonably priced pandora bracelets irrespective of no matter whether you might be susceptible to important in into a persons bracelet with more compact as well as a great deal greater drops. The explanation that this may be a 1st difficulty might be you will would wish to make a decision what measurement drops you decide on being able to in that situation establish a persons perfect Pandora bracelet period.</p> <p>If light red is usually your favored colouring you could possibly be delighted to recognise that leather strand approximately light red (also as african american) is additionally around. How much money you place in right here ought to believe concerning the quantity of <a href="http://www.pandoraukonline.net/">pandora charms uk</a> place on that completed item can have. Commit regarding the higher carry out in the finances when it will be donned a lot of nights. Commonly you will discover basically some forms of fastener forms it's achievable to consider from at the same time. The typical Pandora clasp when positioned seems getting just as a single of several drops, though you might also will need to have the chance regarding the lobster claw clasp. By every in the balances, that Pandora clasp involves fingernails and many proficiency having the ability to open up. In case you're worried about splitting a new nail plate, do not get worried, we've a clasp opener open to support have the clasp open up devoid of risking a persons manicure.</p> <p>Combined with it truly is well known not forgetting fashionable glimpse, it's zero magic why <a href="http://www.pandoraukonline.net/">pandora charms</a> is simply that the incredibly ideal component necklaces select linked with adult females off yrs a lot of countries. Pandora is genuinely a international enterprise specified up best back in that early on 80s roughly Denmark by just For just about every moreover to Winnie Enevoldsen. It genuinely is well-known for it genuinely is LovePods, elegance anklet necklaces furthermore bracelets pandora bracelets additionally to timepieces. Having Pandora necklaces, a new buyer shall be reassured linked with huge satisfaction mainly because elements belonging to the fantastic exceptional are usually carried out to develop numerous objects. Your LovePods selection may well be about because 08 and it is also especially furthermore made from 18k yellow metal moreover to every single for example topaz, spinel, citrine, peridot, amethyst not forgetting, gemstones. Just what can make this distinct genuine is often that the LovePods substantially far more have been created for receiving mixed along.</p> <p>Your most current form of Swiss timepieces has also transpire currently being started on the market this distinct present year or so. Pretty much all are usually proudly Switzerland designed additionally to arrive beautifully produced using a new african american stone from the overhead furthermore to a new sapphire goblet to stop scratch. pandora bracelets uk may be found merchants moreover to internet. And for the explanation that most are clever investment funds, an individual will not probably regret causeing the investment. i am hoping you relished the rapid posting in <a href="http://www.pandoraukonline.net/">pandora online</a>. </p> http://biotechbistro.com/forum/topic/shamballa-rings-my-personal-principal-numerous-shamballa-necklaces#post-416 Wed, 04 Jan 2012 00:27:29 +0000 raxto 416@http://biotechbistro.com/forum/ <p>Are you considering of a very good <a href="http://www.shamballaus.com/">shamballa jewelry</a> fanatic belonging for the hurt tv shows Winning a hot is in fact Kent together with Made in Chelsea and still have observed a striking shamballa gold, also spelt shambahla, obtaining put on merely by all those starring within the acts? If, perhaps you have in that situation looked at ready all these fee in addition to thought a little bit ill through the idea of grinding it out thousands of pounds on one particular. However, coming from On her behalf Coming from You really, you'll be able to aquire your very own variety involving shamballa band, at only your small percentage belonging for the charge, alternatively, the application must listed that will the pretty very same your looked upon in Created in Chelsea finish up being had been bought as a result of For her Via a person, which implies that there continues to be never ever a fantastic call for that to get some duplicate!</p> <p>Here are delivers head 5 made by wonderful variety of Shamballa Jewelry:</p> <p>Mars, 32. 95- This really is unquestionably individual most favourite of each of the, primarily for the reason that it options light bulb ruddy gem bedrooms which can be stiched in a wonderful black color waxed cord. Not simply is it totally hand produced, though it's generally versatile, this implies it truly is in great form in relation for your arm in a relaxed manner.</p> <p>Single, Fuchsia, This magnificent, brilliantly a muslim shamballa bracelet is an invaluable asset, and at <a href="http://www.shamballaus.com/">shamballa bracelets</a> simply 15, too. Specifically what enhanced technique to get involved with all the real shamballa project than to buy your one of a type a single distinct, the same since the versions utilized by indicates of renowns. Having a only fuchsia as well as the bead inside the cord, thereafter 2 lesser fuchsia and also an really beads within the halts of this adaptable strap, it is a really straight forward at this time stylish piece of necklaces that is definitely particular to acquire hold of pretty much all tender with you.</p> <p>Aqua and Hematite, Irrespective of if guys linked with females, that aqua and hematite <a href="http://www.shamballaus.com/">Shamballa Bracelet</a> is without a doubt fantastic, usually as a deal with as a way to your self or for any treat in regards to an added. The light fixture pink lady Czech beads glisten below the gentle and hence put in a sparkle to nearly any attire, regardless of regardless of whether most likely a excursion, as well as producing overnight in town with house girls. Get a item of diamond jewelry which this unique disorders a big variety of looked for option.</p> <p>Range on White, Together with the tones with <a href="http://www.shamballaus.com/">shamballa jewelry store</a> thrown directly into an individual, you could not be unsuccessful using this gorgeously colorful Shamballa Necklace, priced at surely a suitable. Whilst applying array Czech beads weaved upon the whitened, totally adaptable energy cord of up to 30cm, this particular to would be the exceptional compliment.</p> <p>Dual Smokey, This really is generally considerably like average, however using a doubled-up layout, delivering double the real total satisfaction! As an different for only one cord involving Czech beans, this astounding tool includes two instances the volume of cable and also enhance just how much sparking beads- suitable!</p> <p>shamballa anklet bracelets normally really are a choice of Shanballa necklaces brought out by Bracelets Good BRITAIN, and so are at this time created obtainable across the world. The range could be either wide-ranging along with vivid, and also definitely getting priced reasonably, hence you will be not simply specified to encounter precisely the element of jewellery you are considering, but you are common bank balances is just not undergo because of! Your light-weight impression additionally causes it to be pretty best in an effort to don mutually in daytime with morning, <a href="http://www.shamballaus.com/">shamballa bracelets Sale</a> tso you would like did not clear away it from! To know much more concerning Shamballa bracelet pay out a check out to gifts to become with her. </p> http://biotechbistro.com/forum/topic/international-stem-cell-corp-how-is-parthenogenesis-done#post-413 Thu, 29 Dec 2011 16:08:35 +0000 pjbosc 413@http://biotechbistro.com/forum/ <p>San Diego Research Ethics Consortium<br /> Salk Institute for Biological Studies<br /> Parthenogenetic stem cell lines: Ethical considerations</p> <p>International Stem Cell’s Director of Research and Therapeutic Development, Nikolay Turovets, PhD, presents “How is Parthenogenesis Done?”</p> <p>How is Parthenogenesis Done? (ANIMATED)<br /> <a href="http://www.slideshare.net/turovets/how-is-parthenogenesis-done" rel="nofollow">http://www.slideshare.net/turovets/how-is-parthenogenesis-done</a> </p> http://biotechbistro.com/forum/topic/burraco-online#post-409 Wed, 28 Dec 2011 06:56:24 +0000 truculentmystiq 409@http://biotechbistro.com/forum/ <p>hi you all, </p> <p>i was thinking, where the most effective point to join in <a href="http://burracogratis.myblog.it/archive/2011/12/27/burracoonline.html">burraco online</a>. </p> <p>i know from a pal that there's a great software program that i can participate, can you point of whichever ? </p> <p>i thank you loads ! i simply adore that amusement, love - <a href="http://burracogratis.myblog.it/archive/2011/12/27/burraco.html">burraco</a>.</p> <p>have a great day. </p> http://biotechbistro.com/forum/topic/%d7%94%d7%a8%d7%97%d7%a7%d7%aa-%d7%99%d7%95%d7%a0%d7%99%d7%9d#post-397 Sun, 25 Dec 2011 09:06:16 +0000 truculentmystiq 397@http://biotechbistro.com/forum/ <p>hi, I stay in Israel and I'm searching for an excellent somewhere remove birds.<br /> I discovered site with serval suggestions and I like somebody to translate for me please.<br /> thanks in advance</p> <p><a href="http://doveremoval.blogspot.com/">????? ????? </p> http://biotechbistro.com/forum/topic/over-regulation-of-parthenotes-stifles-valuable-scientific-research-sean-kealy#post-370 Fri, 16 Dec 2011 14:11:10 +0000 pjbosc 370@http://biotechbistro.com/forum/ <p>A recent article in Scientific American questioned whether research on stem cell lines derived from unfertilized eggs was too tightly regulated by the federal government. Now that technology allows the creation of stem cells without fertilization, there is no question that federal laws and guidelines are overly restrictive, causing a detrimental effect on valuable scientific inquiry. </p> <p>Since 1996, Congress has included the Dickey-Wicker Amendment in the annual federal budget. This amendment was a conservative reaction to what some considered to be scientific research that showed little respect toward life. </p> <p>For example, speaking to the Senate in 1996, Robert Smith (R-NH) said, “Just because a private party wants to destroy life, why should Government force taxpayers to give their blessing to that act? Let private parties use private money for their ethically challenged experiments.” Similarly, Representative Jay Dickey (R-AR) said, also in 1996, that embroyonic research was “an attack on the sanctity of life,” and pointed out that several pro-life organizations supported the amendment. </p> <p>Please click link below to read the complete article. </p> <p>Source: <a href="http://www.law.upenn.edu/blogs/regblog/2011/12/over-regulation-of-parthenotes-stifles-valuable-scientific-research.ht" rel="nofollow">http://www.law.upenn.edu/blogs/regblog/2011/12/over-regulation-of-parthenotes-stifles-valuable-scientific-research.ht</a> </p> http://biotechbistro.com/forum/topic/introduction#post-243 Fri, 28 Oct 2011 01:28:54 +0000 williams_john 243@http://biotechbistro.com/forum/ <p>When come on this board find it so well.<br /> Actually i registered here 1 day before but try to post here today....<br /> Thanks for welcome me.......... </p> http://biotechbistro.com/forum/topic/safe-rift-platinum-utilizing-the-binge-of-emergency-dread-movement-image-on-the#post-338 Mon, 12 Dec 2011 03:31:52 +0000 ford38 338@http://biotechbistro.com/forum/ <p>Using the flood associated with emergency dread movement image on the net complement sequence near to — Useless space much less high-priced <a href="http://www.riftgoldtoday.com/">Rift gold</a>, Farrenheit.Electronic.Any.Ur., residence operator bad and so forth — it genuinely is sort of remarkable to glance at an escape by zombies arriving by implies of frosted goblet home glass windows collectively with sustain some time within inside the fantasy-lite realm of Azeroth. even so Valafar associated with about Exodar was within a place to appear through a tiny amount of terror even the harmless landscaping involving Amazing. concerning the relatively lowest that zombie is not jumping apart from the heating thank collectively with acquiring that person. This dude or ladies appears acquiring appreciably a fabulous offer more possibly to support you some tea and permit you acquiring the evening within their deserted farmhouse <a href="http://www.riftgoldtoday.com/">rift platinum</a> platinum, delivering you provide to not sleep collectively with his about three gorgeous zombie children.<br /> Do you have practically any unconventional affordable rift platinum, stunning or possibly fascinating Up-date pics which could possibly be merely just collecting dirt within your screenshots folder? I’d would instead uncover them upon All-around Azeroth legit rift platinum! Discussing the screenshot is by that attributes a replicate inside the probability as well getting a quickly explanation inside the world. you can possibly be highlighted perfect ideal right here subsequent purchase rift platinum!<br /> Don’t overlook to incorporate your participant name, host and/or guild in circumstance you call up for that product or organization stated. You call up up for to broad range inside the phrase “Azeroth” as element of your publish getting a carry out end result it does not get lightly fluffed for that unsolicited mail bin. All of us definitely like whole show display pics without possessing any the Urinary incontinence displaying — hold benefit of alt-Z to eradicate it. Please, no appreciably a fabulous offer more battleground scoreboards rift platinum for sale, Val’kyr about facilitates rift platinum, or pics inside the Ninja Turtles within of Dalaran. appreciably a fabulous offer more mature screenshots is near to perfect here. </p> http://biotechbistro.com/forum/topic/the-avoca-group-announces-consortium-on-quality-management-and-oversight-sponsor#post-324 Thu, 08 Dec 2011 08:00:49 +0000 chelsea.scorr 324@http://biotechbistro.com/forum/ <p>For Immediate Release<br /> Media Contact:<br /> Kelly Sladek<br /> Director of Marketing Communications<br /> <a href="mailto:kelly@scorrmarketing.com">kelly@scorrmarketing.com</a><br /> 308.237.5567 </p> <p>General Information:<br /> Caryn Laermer<br /> Senior Manager, Quality Consortium<br /> <a href="mailto:caryn.laermer@theavocagroup.com">caryn.laermer@theavocagroup.com</a><br /> 609.799.0511</p> <p>The Avoca Group Announces Consortium on Quality Management and Oversight Sponsored by Eli Lilly and Pfizer </p> <p>PRINCETON, NJ (December 8, 2011) – The Avoca Group, an industry-leading research organization specializing in clinical outsourcing and client service, today announced the formation of the Quality Consortium, a pharmaceutical industry consortium focused on quality management.</p> <p>“The Avoca Group’s 2011 Report on Quality and CRO Oversight revealed some insightful data regarding industrywide dynamics between sponsors and CROs,” said Patricia Leuchten, president and CEO of The Avoca Group. “Through our analysis we identified opportunities to potentially improve outcomes through collaboration in quality management and metrics. The Quality Consortium will effectively share industry best practices and establish new standards.”</p> <p>Under the direction and guidance of Leuchten and The Avoca Group, the Quality Consortium will bring together lead sponsors Eli Lilly and Pfizer, other pharmaceutical and biotech companies, and leading CROs to create standards for quality management, initially with a focus on quality agreements and metrics. The consortium’s long-term goal is the development of a new paradigm in the industry’s approach to quality management and partnering with CROs to ensure high quality and risk mitigation.</p> <p>Jeff Kasher, Ph.D., vice president and chief operating officer, global clinical development, at Eli Lilly and co-sponsor of the Quality Consortium, said: “At Eli Lilly, we place a high priority on the success of our CRO partnerships. We are excited about our sponsorship and participation in the Quality Consortium and look forward to the possibility of quality oversight standardization. We believe that by establishing industry standards for quality oversight we can optimize our partnerships with CROs and improve our ability to ensure data integrity and patient safety.”</p> <p>In addition to sponsors Eli Lilly and Pfizer, the consortium continues adding members, including Amgen, Astellas, Biogen Idec, Bristol-Myers Squibb, Cubist, GlaxoSmithKline, Grunenthal and Purdue Pharma. Members will collaborate with industry professionals, share quality management best practices with colleagues and experts, gain specific tools and knowledge that will have immediate impact in enhancing their organizations’ approach to oversight, and identify and proactively address current gaps between pharmaceutical sponsors and CROs. </p> <p>Membership is still available for a limited time to qualifying organizations. The consortium’s work begins this month and the inaugural Quality Summit to review and share member insights and analyses, sponsored by PharmaNet/i3, is scheduled for May 2012. For membership inquiries or to become part of the consortium, contact Caryn Laermer at 609-799-0511 or visit the consortium’s website.</p> <p>About The Avoca Group<br /> The Avoca Group is an industry-leading organization providing survey research, consulting services and training in the areas of clinical outsourcing, business development, strategic alliances and client service. Founded by industry veteran Patricia Leuchten in 1999, the company works exclusively in the health care industry and has a focus on relationship management.<br /> ### </p> http://biotechbistro.com/forum/topic/cri-worldwide-and-lifetree-clinical-research-announce-new-company-name%e2%80%94cri-lifet#post-323 Wed, 07 Dec 2011 10:18:20 +0000 chelsea.scorr 323@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>PR Contact:<br /> Kelly Sladek<br /> SCORR Marketing<br /> 308.237.5567<br /> <a href="mailto:Kelly@scorrmarketing.com">Kelly@scorrmarketing.com</a></p> <p>CRI Worldwide and Lifetree Clinical Research Announce New Company Name—CRI Lifetree</p> <p>(Mount Laurel, NJ; December 7, 2011) – CRI Worldwide, a specialized research organization with concentrated expertise in psychiatry, pediatrics, pain and neurology, which recently acquired Lifetree Clinical Research®, has united the two companies under the new name, CRI Lifetree. Accompanying the new name is its strategically focused tagline, “Innovative Solutions. Reliable Results.”</p> <p>The company integrates CRI’s leadership in psychiatry and expertise in complex studies with Lifetree’s widely recognized clinical trial management and site expertise in Phase I-III pain management and abuse liability studies. Bringing the companies together under one unified name streamlines all branding, communication, and SOPs and processes across the two companies. </p> <p>“CRI Lifetree is grounded in sound science,” stated Alice Jackson, CRI Lifetree president. “We give our clients the innovation they are looking for—from ‘entrepreneurial’ first-in-human study design to solutions for specialized human abuse liability research.”</p> <p>“We’re off to a great start; the company is busier than ever,” commented Jeff Kinell, CRI Lifetree CEO. “Since the acquisition, our clients have continued to receive the highest quality service and results, while enriching the early stage clinical research landscape for our sponsors.”</p> <p>As a clinical research provider with more than 25 years of expertise, CRI Lifetree is a leader in specialized, multi-therapeutic inpatient and outpatient early stage research. The organization offers a broad range of Phase I-IV services and rapid access to specific patient populations to meet the requirements of complex clinical research programs.</p> <p>About CRI Lifetree<br /> CRI Lifetree is a leader in specialized, multi-therapeutic early stage research providing innovative solutions, high quality and timely results to sponsors. The company has significant expertise in psychiatry, pediatrics pain and neurology, analgesia pain model development, sleep medicine and addiction, and human abuse liability. CRI Lifetree offers a broad range of Phase I-IV services and rapid access to specific patient populations to meet the requirements of complex clinical research programs. Our team works with sponsors in the design and successful execution of drug development programs from first-in-human/MTD, clinical trial management and proof-of-concept, to clinical monitoring and data management/validation/auditing. With sites in New Jersey and Salt Lake City, the company conducts inpatient and outpatient clinical research in special populations and healthy volunteers. For additional information about CRI Lifetree, visit <a href="http://www.criww.com" rel="nofollow">http://www.criww.com</a> and <a href="http://www.lifetreeresearch.com" rel="nofollow">http://www.lifetreeresearch.com</a>. </p> <p>### </p> http://biotechbistro.com/forum/topic/camargo-plans-future-growth-of-company-with-the-addition-of-vice-president-of-co#post-286 Tue, 06 Dec 2011 10:12:53 +0000 chelsea.scorr 286@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>CONTACT:<br /> Kelly Sladek<br /> SCORR Marketing<br /> 308.237.5567<br /> <a href="mailto:kelly@scorrmarketing.com">kelly@scorrmarketing.com</a></p> <p>Camargo Plans Future Growth of Company with the Addition of Vice President of Corporate Development </p> <p>Cincinnati, OH; December 6, 2011) – Camargo Pharmaceutical Services, an end-to-end drug development service provider specializing in the 505(b)(2) process, has set a course for the future growth of the company by appointing Mark Bolin as vice president of corporate development.</p> <p>In his new role, Bolin will utilize over 25 years of pharmaceutical and health care industry experience to advance the company through strategic financial and technical partnerships to meet the needs of the marketplace. An increasing number of new drug approvals are using the 505(b)(2) pathway, which requires full safety and effectiveness reports but allows the use of other companies’ study results, thereby taking a fraction of the time and cost required by traditional paths.</p> <p>“Camargo’s recent expansion with the opening of our Durham, N.C., office and the potential to open additional offices will extend our company’s reach to clients around the globe, while making our extensive regulatory expertise available to meet the increasing demand in formulation, preclinical and clinical services,” stated Ken Phelps, president and CEO. “Mark will serve as the business arm and his substantial experience setting companies up for growth via financial and operational management will be an asset to Camargo.”</p> <p>Prior to his employment at Camargo, Bolin served as a founding member and chief financial officer of Ricetta Rx Holdings LLC. While there, he helped secure a long-term care pharmacy business through acquisition and organic growth. Bolin was responsible for identifying and targeting acquisition candidates, negotiating acquisition term sheets and asset purchase agreements and managing the financial operations of the company. The company was sold in a series of transactions in 2008 and 2011 to both public and private equity backed entities. Bolin is a certified public accountant and is a graduate of the University of Kentucky. </p> <p>About Camargo Pharmaceutical Services<br /> Camargo Pharmaceutical Services is an end-to-end drug development service provider specializing in the 505(b)(2) approval pathway. Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulating and testing the drug product, to conducting clinical studies and FDA application submissions. Connect with Camargo on LinkedIn, the President’s blog or visit <a href="http://www.camargopharma.com" rel="nofollow">http://www.camargopharma.com</a> for more information.</p> <p>### </p> http://biotechbistro.com/forum/topic/thomas-sabo-charms-for-the-acceptable-events#post-283 Mon, 05 Dec 2011 22:32:58 +0000 jewellerytting 283@http://biotechbistro.com/forum/ <p>Jewellery alternation by <a href="http://www.pandoraustralia.net/"><strong>pandora australia</strong></a> appears from Germany, reluctant towards the aberrant concepts of architecture to advance little, trendy argent posts for everyone. Argent supplied by him consists of armlet which are colourful, admirable architecture rings, adventurous and admirable instant, and assorted extra array of silver. Not by yourself this, addition alternation with archetypal architecture is abounding of physical appearance which could apparel any occasion. It makes usage of adorable way inside the physique up curve to adapt admirable physical appearance to attain a mark around the hearts of abounding adolescent women.1980?s was the calendar year if Thomas Sabo alien his jewellery. Hard work has become set in to actualize reliable ornaments in argent with aberrant good quality, which after-effects in formatting it?s aberrant type. The two a great deal of classical alternation by Thomas Sabo; Thomas Sabo Charms Club and argent Accumulating were developed and go with in beginning pieces of models. Its stated about charms which they represent our chic and obsession. If you want to complete a staying feel appropriate and attending altered amidst the group, it is a complete way to achieve this.For lovers of admirable argent jewellery, thomas sabo jewellery is a acclaimed brand. Individuals are in adulation with the complete and avant-garde styles of jewelry. It's the <a href="http://www.pandoraustralia.net/"><strong>pandora charms australia</strong></a> agreeableness club accumulating by the aggregation which occurs to motion the plenty of acclaimed products. On your acceptable events annihilation might be bigger compared to accumulating of adornment supplied by Sabo.The accumulating of Thomas Sabo?s accumulating for Fall-Winter 2009 is actually a acerbity a part of lovers of admirable silver. This ambit obtained its afflatus anatomy the accepted iconic child alleged Barbie. It had been inside the year 2009 that Barbie accomplished the age of 50. Abounding charms to the winter ended up distinctively alien through the aggregation to admire Barbie?s 50th anniversary. The accumulating includes of admirable armlet models and chaplet designs which might be distinctive.<br /> The accumulating provides something for all with altered visual appeal taste. This really is regardless of the actuality that any person is hunting for archetypal types, Gothic types, bashful designs, and many others.They accomplish up as absolute allowance to bless Valentine?s Day or any extra suitable break along with your admired 1. The admirable accumulating of necklaces and bracelets are in fact perfect. The complete and diverse models are apprenticed to accompany about some aberration inside the faculty of appearance to the recipient. The exclusivity supplied by these jewel pieces will attain them abatement in adore <a href="http://www.pandoraustralia.net/"><strong>pandora bracelets</strong></a>. The accumulating delivers a thing for any person and also to garments every budget. </p> http://biotechbistro.com/forum/topic/davita-labs-appoints-new-vice-president-and-general-manager#post-282 Thu, 01 Dec 2011 09:23:35 +0000 chelsea.scorr 282@http://biotechbistro.com/forum/ <p>DaVita Labs Appoints New Vice President and General Manager</p> <p>FORT LAUDERDALE, Fla. (Dec. 1, 2011) –DaVita Labs, a chronic kidney disease specialty laboratory, today announced the appointment of Leslie Mirani as DaVita Labs’ new vice president and general manager. </p> <p>Mirani brings to DaVita Labs™ more than 25 years experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. Mirani’s previous roles included working for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years. She graduated from Ohio State and is a registered clinical dietician.</p> <p>“Leslie’s extensive background will give us the momentum to move forward with our future goals and continue to provide great service, quality, technology and education to keep us at the front end of new developments within the industry,” said DaVita Labs President Chris Rucker.</p> <p>DaVita Labs has 86,700 square feet dedicated to its state-of-the-art clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Fla. The laboratories feature the latest in renal-specific methodology and technology for delivering quality test results. The DaVita Labs clinical laboratory team is led by experienced scientists and pathologists, and receives formal guidance from top nephrologists in the industry.</p> <p>DaVita and DaVita Labs are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.</p> <p>About DaVita Labs<br /> DaVita Labs, a division operating within DaVita Inc., provides quality, on-time, accurate results to help effectively identify and manage kidney patients across the nation. As a cutting-edge chronic kidney disease (CKD) specialty laboratory, DaVita Labs features the latest in end stage renal disease-specific methodology and technology for delivering quality dialysis test results. DaVita Labs is fully accredited by the federal and state governmental agencies, and the College of American Pathologists. For more information, please visit <a href="http://www.davitalabs.com" rel="nofollow">http://www.davitalabs.com</a> or call 877-200-3181. </p> <p>About DaVita<br /> DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Sept. 30, 2011, DaVita operated or provided administrative services at 1,777 dialysis facilities, serving approximately 138,000 patients. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit <a href="http://www.davita.com" rel="nofollow">http://www.davita.com</a>.</p> <p>###</p> <p>Contact Information<br /> Media:<br /> Vince Hancock<br /> (303) 405-2272<br /> <a href="mailto:Vince.hancock@davita.com">Vince.hancock@davita.com</a> </p> http://biotechbistro.com/forum/topic/international-stem-cell-corporation-to-present-immune-matching-research-advance#post-278 Tue, 29 Nov 2011 16:16:08 +0000 pjbosc 278@http://biotechbistro.com/forum/ <p>International Stem Cell Corporation to Present Immune Matching Research Advances at Cell Science and Stem Cell Research 2011 Conference</p> <p>Executives from International Stem Cell Corporation (OTCBB:ISCO), a biotechnology company specializing in the research and development of stem cell-based therapies, will be presenting advances made in its research programs related to the use of immune-matched patient-specific parthenogenetic stem cells for neurological applications and genetic liver diseases at Cell Science 2011 in Philadelphia on November 29th.</p> <p>Vice President Ruslan Semechkin, Ph.D., will open the conference and discuss the latest trends in the use of stem cells to treat diseases of the central nervous system. A follow-on presentation will demonstrate that functional dopaminergic neurons can be successfully obtained from human parthenogenetic stem cells. Alina Ostrowska, Ph.D., the Company's Director of Translational Research, will present a new method of obtaining highly-enriched cultures of hepatocyte-like cells from pluripotent human stem cells.</p> <p>Dr Semechkin comments, "I'm honored to be opening this conference and to be debating the latest advances in stem cell therapies. ISCO will also be presenting the most recent results from two of our most important research programs, where we continue to further characterize our parthenogenetic stem cell lines and their ability to form functioning liver-like cell and functioning neuron-like cells."<br /> ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human pluripotent stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals. ISCO maintains the world's largest collection of research-grade hpSC lines.</p> <p>About International Stem Cell Corporation<br /> International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>.</p> <p>To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&#38;to=ea&#38;s=0.</p> <p>Forward-looking Statements<br /> Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. </p> http://biotechbistro.com/forum/topic/a-brief-history-of-ornamental-bracelets-goes-long-ago-to-the-time-of-the-ancient#post-272 Thu, 24 Nov 2011 00:57:26 +0000 cici112 272@http://biotechbistro.com/forum/ <p>There are very many designer handbags that will give a person a stylish look to complement their outfit.<strong><a href="http://www.louisvuittonsbutiken.com/">neverfull louis vuitton</a></strong> , Finding a perfect bag that will go with every outfit in the closet will not cost much as long as a person knows how to be cost savvy.<strong><a href="http://www.mbtentrenadoresventa.com/">zapatos</a></strong> , There are very many places where a person can get hot bags at prices that are quite unbelievable.</p> <p>There are so many super deals that a person can find, especially from the internet or from the outlets where they have a sale. There is so much information that a person will get from the internet, from the discounted prices to the nearest places where they can get these bags. This will allow a person to plan on the money that they will be spending on these bags.</p> <p>One of the things that the women will consider is the bag that will go well with their figure and the style that will work best for them. Women will consider their body size and shape. For example, a slim and tall woman will go for a bag that is round or square. There are different sizes and shapes that will suit women of different body figures.</p> <p>Even if one cannot get the original design bags, there are those imitations that are cheaper and will look just the same the only thing will be the quality. It is very hard to get an imitation that looks like the real thing but at least, it will work out for the person before they can get enough money to get the original design.</p> <p>The color of the bag is also very important. The good news is that today bags are available in so many colors. For this reason, a person can buy the same bag but in different colors. There are those printed bags that are always in fashion and the plain ones that are always practical to carry. The choice will depend in the outfit that the woman will be wearing.</p> <p>Researching on the different places that are near where a person can get the bag will save a lot of time and energy. This is some that can easily be dime from the internet rather than choosing to move from one shop or the other which may be very tiring and time consuming. Being updated on all the new designs and designer's will also be very helpful.</p> <p>Thinking about the price is very important. The more money a person will have, the more they will be able to get. This is in terms of number and quality of the bags. Those that will not plan with what they will be spending more than they can actually afford. Before a person decides to go shopping, they should carry enough money to avoid impulse buying.</p> <p>Currently, there is a very huge collection of so many handbags so a buyer will not feel short of the choices that they have to make. High quality products as well as the ones that are trendy are all there, so it will be up to the person to get what they want. </p> http://biotechbistro.com/forum/topic/acr-image-metrix%e2%80%99-dr-bruce-hillman-receives-gold-medal-at-rsna-annual-meeting#post-270 Tue, 22 Nov 2011 09:45:30 +0000 chelsea.scorr 270@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE </p> <p>Contact:<br /> Shawn Farley<br /> Public Relations Manager<br /> 703.648.8936<br /> <a href="mailto:sfarley@acr.org">sfarley@acr.org</a></p> <p>ACR Image Metrix’ Dr. Bruce Hillman Receives Gold Medal at RSNA Annual Meeting</p> <p>(Philadelphia, PA; November 22, 2011) – ACR Image Metrix™, a global imaging contract research organization (CRO) with expertise in imaging trial design, is proud to announce Bruce Hillman, M.D., FACR, is one of three recipients of the gold medal, the Radiological Society of North America’s (RSNA) highest honor. Dr. Hillman, ACR Image Metrix’ founder and chief scientific officer, will accept his award at the RSNA Annual Meeting, which takes place November 27-December 2, 2011, in Chicago.</p> <p>RSNA gold medals are presented each year to individuals who have rendered exemplary service to the science of radiology and who have received unanimous approval by the RSNA Board of Directors—a tradition that originated in 1919. ACR Image Metrix will be exhibiting at booth #9346 in the McCormick Place Convention Center north building during the RSNA show. </p> <p>Dr. Hillman has authored and co-authored more than 170 studies appearing in major medical publications and has been selected Who’s Who in Medicine and Healthcare and Who’s Who in the World. Dr. Hillman formerly served as chair and principal investigator of the American College of Radiology Imaging Network® (ACRIN®). Dr. Hillman has received 22 grants and nearly $200 million in grant funding, including the National Cancer Institute (NCI) UO-1 award, which led to the founding of ACRIN in 1999.</p> <p>Dr. Hillman is a fellow of the American College of Radiology® (ACR®), a member of the ACR Board of Chancellors and an honorary fellow of three foreign national radiological societies.</p> <p>“ACR Image Metrix would like to congratulate Dr. Hillman on this honor,” stated Chief Executive Officer Dr. Harvey Neiman, FACR. “His work within the radiological industry is outstanding, and we are proud of his accomplishments.” </p> <p>As a leading imaging CRO, ACR Image Metrix specializes in providing services to assist pharmaceutical, biotech and medical device companies around the world.</p> <p>About ACR Image Metrix™<br /> ACR Image Metrix™, an imaging contract research organization (CRO) located in the American College of Radiology Clinical Research Center in Philadelphia, applies imaging techniques to improve the efficiency of drug and medical device development programs. The world-class team of radiologists and imaging scientists at ACR Image Metrix works with pharmaceutical, biotech and medical device companies to integrate the appropriate imaging technologies, modalities and clinical design techniques into their imaging studies. ACR Image Metrix has years of experience utilizing state-of-the-art technologies to provide a complete line of imaging services from site qualification and training, study initiation, image management, reader studies and much more. Connect with ACR Image Metrix™ on LinkedIn and Twitter.</p> <p>### </p> http://biotechbistro.com/forum/topic/utilizing-health-outcomes-data-to-drive-company-decision-making#post-265 Fri, 11 Nov 2011 12:16:17 +0000 MWestergaard87 265@http://biotechbistro.com/forum/ <p>In this era of pricing pressures, access barriers and strong demand from all stakeholders for more detailed outcomes information, pharmaceutical companies have come to appreciate the importance of demonstrating and articulating the value of their products. Now, stakeholders are increasingly relying on Health Economics and Outcomes Research (HEOR) information to fully understand product value in healthcare and its potential in real-world clinical practice.</p> <p>Kevin Mayo is Senior Director, Health Outcomes &#38; Pharmacoeconomics; Pharmacoeconomics (HOPE) at Endo Pharmaceuticals. Kevin has an extensive international appreciation for new product development and commercialization, Health Economics &#38; Health Outcomes Research, Health Technology Assessment and for developing Market Access &#38; Pricing Strategies gained during his 15 years working within the pharmaceutical industry in leadership roles.</p> <p>Dr. Mayo answered a series of questions written by marcus evans before the upcoming 3rd Annual Health Outcomes &#38; Pharmacoeconomics Research Conference, January 30-31, 2012 in Philadelphia, PA. All responses represent the view of the Dr. Mayo and not necessarily those of Endo Pharmaceuticals. (Note that the responses have been approved by Endo Pharmaceuticals.)</p> <p>What are some key differences in strategy and application for market access and outcomes research in the U.S. versus other major markets (i.e. South America, Europe and Asia)?</p> <p>KM: Market Access mechanisms can be classified as Supply Side (focused upon the manufacturer) or Demand Side (focused upon the physician and/or patient) cost containment / market access regulations. Today, most nations use a combination of mechanisms and there is less (relative to historically) variation among the mechanisms chosen. The major difference between nations is the methodology that is used to implement the mechanisms. Implementation tends to occur along a continuum from limited control, to control via innovation ratings / clinical comparisons and finally to control via formal health economic evaluations. The USA with the new establishment of the Patient Centered Outcomes Research Institute (PCORI) and health reform activities is currently experiencing the “(clinical) comparative effectiveness” stage of evolution. Many other countries have already or are in the process of adopting formal health economic evaluation processes as part of their new health technology assessments.</p> <p>In the years that you've been involved in the pharmaceutical industry, how has the emphasis on health economics and health outcomes research changed? How does HEOR/HOPE fit into the overall company strategy?</p> <p>KM: Since I joined the life science industry in 1997, the activities and deliverables of a Health Outcomes and Health Economics function have remained basically the same (incorporating endpoints in clinical trials, developing payer communication tools such as dossiers, budget impact and health economic models) but with improved econometric techniques and access to data. However, a profound change has occurred in our function’s involvement in internal decision making. When I first joined the industry, our departments were viewed as “support” functions to clinical development and/or managed markets organizations. Today, our team’s analyses and insights are a core consideration driving licensing, clinical development go/no go stage gates, commercial and pricing strategy decisions. Our modern contributions provide a stronger direct link to shareholder value and our insights are more understood and appreciated by senior management.</p> <p>How, in your opinion, do observational investigations relate to and impact comparative effectiveness research (CER)?</p> <p>KM: Although randomized controlled trials (RCT) are superior to quasi-experimental designs in regards to internal validity, they are also characterized by a lack of generalizability (external validity). RCTs have an important role in new product development; however, their use is often impracticable in answering the questions of most relevance to our company’s stakeholders (physicians, patients, payers and politicians). One of the most existing recent advancements from my perspective in observational research methods is the convergence of the Campbell (social sciences) and Rubin (statistics) Causal Models. Donald Campbell’s lasting legacy to our profession will be his emphasize upon the importance of quasi-experimental research designs. Donald Rubin has provided us with the statistical techniques such as propensity score matching within the potential outcomes framework that allow us to control for unobserved covariants. Merging these two great schools of thought could dramatically accelerate the creation and adoption of superior observational research methods.</p> <p>The marcus evans 3rd Annual Health Outcomes &#38; Pharmacoeconomics Research Conference will take place January 30-31, 2012 in Philadelphia, PA. </p> <p>For more information, please contact:<br /> Michele Westergaard<br /> Marketing/PR Coordinator<br /> marcus evans<br /> 312-540-3000 ext. 6625<br /> <a href="mailto:Michelew@marcusevansch.com">Michelew@marcusevansch.com</a></p> <p>About marcus evans<br /> marcus evans conferences annually produce over 2,000 high quality events designed to provide key strategic business information, best practice and networking opportunities for senior industry decision-makers. Our global reach is utilized to attract over 30,000 speakers annually, ensuring niche focused subject matter presented directly by practitioners and a diversity of information to assist our clients in adopting best practice in all business disciplines. </p> http://biotechbistro.com/forum/topic/international-stem-cell-corp-announces-the-launch-of-two-new-international-sales#post-263 Thu, 10 Nov 2011 12:09:32 +0000 pjbosc 263@http://biotechbistro.com/forum/ <p>"International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care"</p> <p>International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website <a href="http://www.lifelineskincare.com" rel="nofollow">http://www.lifelineskincare.com</a>.</p> <p>The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.</p> <p>"I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."</p> <p>Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.</p> <p>"In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."</p> <p>Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.</p> <p>About International Stem Cell Corporation<br /> International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>.</p> <p>To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&#38;to=ea&#38;s=0.</p> <p>Forward-looking Statements<br /> Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. </p> http://biotechbistro.com/forum/topic/international-stem-cell-corp-comments-on-wsj-article-%e2%80%9chope-for-stem-cell#post-262 Wed, 09 Nov 2011 15:58:37 +0000 pjbosc 262@http://biotechbistro.com/forum/ <p>International Stem Cell Corporation Comments on WSJ Article “Hope for Stem-Cell Treatment of Parkinson's”</p> <p>Hope for Stem-Cell Treatment of Parkinson's BY GAUTAM NAIK – The Wall Street Journal HEALTH</p> <p>“Researchers have used stem cells obtained from human embryos to successfully treat Parkinson's disease in mice and rats, a key step in the quest to develop a similar approach for people.</p> <p>In a study published Sunday in the journal Nature, scientists described how they converted human embryonic stem cells into nerve cells that produced the brain chemical dopamine. When these nerve cells were transplanted into the brains of mice and rats, they released dopamine and got rid of the animals' Parkinson's symptoms. The cells were also successfully transplanted into rhesus monkeys, whose biology is closer to that of humans.”</p> <p>SOURCE - To read the complete article on The Wall Street Journal HEALTH site, please click here: <a href="http://online.wsj.com/article/SB10001424052970204621904577018133476441946.html" rel="nofollow">http://online.wsj.com/article/SB10001424052970204621904577018133476441946.html</a></p> <p>Comments from International Stem Cell Corporation:</p> <p>International Stem Cell Corporation (ISCO) announced in July 2011 the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells. The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSCs), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).</p> <p>Dr. Andrey Semechkin, Co-Chairman and CEO of ISCO, comments: “The ability of neuronal cells to become a specific type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”</p> <p>Forward-looking Statements<br /> Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.</p> <p>Source - <a href="http://online.wsj.com/article/SB10001424052970204621904577018133476441946.html" rel="nofollow">http://online.wsj.com/article/SB10001424052970204621904577018133476441946.html</a> </p> http://biotechbistro.com/forum/topic/video-stemcelltv-interviews-donna-queen-of-lifeline-skin-care#post-260 Tue, 08 Nov 2011 15:59:41 +0000 pjbosc 260@http://biotechbistro.com/forum/ <p>StemCellTV interviews Donna Queen of Lifeline Skin Care at the California Academy of Cosmetic Surgery Annual Conference in San Diego October 2011.</p> <p>Please click here to view the video - <a href="http://bit.ly/rM3Zz2" rel="nofollow">http://bit.ly/rM3Zz2</a> </p> http://biotechbistro.com/forum/topic/snbl-usa-appoints-mark-t-crane-as-vice-president-of-business-development#post-254 Mon, 07 Nov 2011 07:37:32 +0000 chelsea.scorr 254@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>CONTACT:<br /> Michelle Taylor, MA<br /> Marketing Manager<br /> 425.322.1950<br /> <a href="mailto:mtaylor@snblusa.com">mtaylor@snblusa.com</a></p> <p>SNBL USA Appoints Mark T. Crane as Vice President of Business Development</p> <p>Everett, WA – November 7, 2011 – SNBL USA, one of the nation’s leading providers of preclinical services, is pleased to announce new executive leadership with the arrival of Mark T. Crane as Vice President of Business Development. As the new VP, Mr. Crane will have overall responsibility for the company’s marketing, sales and business development efforts and will be tasked with driving the growth of SNBL USA's business model and fostering positive relationships with new and current customers. </p> <p>Mr. Crane joins SNBL USA from Ricerca Biosciences where he served as Vice President of Global Sales and Marketing. He has held similar positions at Bridge Pharmaceutical, Inc. (formally GeneLogic, Inc.), Quest Pharmaceutical Services, and MDS Pharma Services. With over 25 years of industry experience, Mr. Crane is an accomplished executive with extensive expertise in management, business development, and marketing. His preclinical market knowledge and experiences from the pharmaceutical and contract research organization industries will be of significant value to SNBL USA and all its customers. </p> <p>"We wanted to bring someone in to focus solely on business development and Mark is a perfect fit,” said Dr. Thomas Beck, SNBL USA president and COO. “As a seasoned industry executive, Mark’s proven leadership skills will be invaluable as we plan for the coming new year and continue to refine and execute our strategy.”</p> <p>About SNBL USA, Ltd.<br /> Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit <a href="http://www.snblusa.com" rel="nofollow">http://www.snblusa.com</a>.</p> <p>SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.<br /> ### </p> http://biotechbistro.com/forum/topic/abzyme-therapeutics-licenses-sumopro-from-lifesensors#post-247 Thu, 03 Nov 2011 11:34:07 +0000 cgorsky 247@http://biotechbistro.com/forum/ <p>Abzyme Therapeutics, LLC was founded to develop human therapeutic monoclonal antibodies. They have licensed LifeSensors protein expression platform, SUMOpro™ to further their monoclonal antibody production.</p> <p>MALVERN, PA -- November 3, 2011 -- Abzyme Therapeutics, a new biotechnology company dedicated to developing methods to generate human monoclonal antibodies for the treatment of disease, announced today that they have entered into an exclusive agreement with LifeSensors to license their proprietary protein expression platform, SUMOpro™. Enhanced protein expression is key to the evolution and development of antibodies and the LifeSensors SUMOpro™ technology is a protein expression platform that can dramatically enhance overall protein production through increased protein translation, solubility, and stability.</p> <p>“The use of Abzyme Therapeutics’ systems and platforms will allow monoclonal antibodies to be used for the treatment of Alzheimer’s disease, cancer, autoimmune disease, and infectious diseases” said Dr. Tauseef Butt, co-founder and Chair of Abzyme Therapeutics Board of Directors. </p> <p>Abzyme is currently focused on treating Alzheimer’s by developing proteolytic antibodies capable of hydrolyzing and clearing beta-amyloids from the human blood stream. These antibodies are designed to hydrolyze multiple antigen target molecules and overcome the problem of resistance, providing increased benefit at reduced doses. Alternatively, the generation irreversibly and repeatedly of these antibodies in the future will be critical in the development of treatments for cancers and other diseases.</p> <p>Abzyme Therapeutics, LLC has established its headquarters in the Great Valley Technology Center, Malvern, PA and aims to exploit their platforms for the development of novel therapeutic antibodies that will offer affordable medicines with increased benefit, requiring reduced dosages. With therapeutic antibody evolution platforms based on intracellular (iHUMab)/extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics is capable of generating highly diversified human antibody repertoires. For more information please visit <a href="http://www.abzymetx.com" rel="nofollow">http://www.abzymetx.com</a>. </p> <p>LifeSensors, Inc. is the leading producer of innovative research tools for the ubiquitin and ubiquitin-like protein pathways. Its prokaryotic and eukaryotic protein expression platforms SUMOpro™ and SUMOstar™ are used worldwide to overcome bottlenecks in protein production. LifeSensors’ technologies enable research once difficult to achieve by using a wide variety of high quality tools including enzymes, substrates, and inhibitors. For more information please visit <a href="http://www.lifesensors.com" rel="nofollow">http://www.lifesensors.com</a>.</p> <p>Contact:<br /> LifeSensors, Inc.<br /> Email: <a href="mailto:info@lifesensors.com">info@lifesensors.com</a><br /> Phone: (610) 644-8845<br /> <a href="http://www.lifesensors.com" rel="nofollow">http://www.lifesensors.com</a><br /> Or<br /> Abzyme Therapeutics, LLC<br /> Dr. Hiep Tran, Chief Scientific Officer<br /> Email: <a href="mailto:info@abzymetx.com">info@abzymetx.com</a><br /> Phone (610) 990-7531 </p> http://biotechbistro.com/forum/topic/ricerca-biosciences%e2%80%99-taiwan-facility-celebrates-40th-anniversary#post-246 Wed, 02 Nov 2011 19:45:42 +0000 chelsea.scorr 246@http://biotechbistro.com/forum/ <p>FOR IMMEDIATE RELEASE</p> <p>CONTACT:<br /> Kelly Sladek<br /> SCORR Marketing<br /> Phone: 308.237.5567<br /> <a href="mailto:kelly@scorrmarketing.com">kelly@scorrmarketing.com</a></p> <p>Ricerca Biosciences’ Taiwan Facility Celebrates 40th Anniversary</p> <p>(Taipei, Taiwan; November 3, 2011) – Ricerca Biosciences, an integrated preclinical contract research organization (CRO) providing services to the pharmaceutical industry, is celebrating 40 successful years of practice in its Taipei, Taiwan, location on November 11, 2011.<br /> The facility has made many significant changes and improvements throughout the last four decades, including an enhanced lab environment and extended operational capabilities.<br /> “Over the past 40 years, we have worked on more than a half-million testing substances in a wide battery of pharmacology assays,” stated Fong-Chi Cheng, Ricerca Taiwan senior director and site manager. “Because of our continuous improvements, the facility now performs studies for over 500 clients each year.”<br /> In June 2011, the Taiwan facility was awarded the Taipei Labor Bureau’s Titiana Award, or Happiness Enterprise Award, for providing a safe work environment, friendly workplace, excellent training development and good compensation and benefits to workers. Currently, the company is working to acquire its certificate from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in 2013.<br /> “Ricerca is very proud of our Taiwan facility. It has provided top-quality service for 40 years, and we are looking forward to the future and what it holds,” said Ian Lennox, CEO of Ricerca.<br /> Ricerca Biosciences provides a full range of preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability.</p> <p>About Ricerca Biosciences<br /> Ricerca Biosciences, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds AAALAC certification.<br /> ### </p> http://biotechbistro.com/forum/topic/seeking-alpha-article-3-contenders-to-be-the-first-profitable-stem-cell-compan#post-245 Wed, 02 Nov 2011 13:54:24 +0000 pjbosc 245@http://biotechbistro.com/forum/ <p>Seeking Alpha is a stock market news and financial analysis website, including free earnings call transcripts, investment ideas and ETF &#38; stock research written by finance experts. Ryan Pollock recently initiated coverage on International Stem Cell Corporation (ISCO). Although the views and opinions are Mr. Pollock’s own and not necessarily those of ISCO, we thought you would be interested in his insights about our company.</p> <p>To read the complete article 3 Contenders To Be The First Profitable Stem Cell Company, please visit <a href="http://seekingalpha.com/article/298781-3-contenders-to-be-the-first-profitable-stem-cell-company?source=from_friend" rel="nofollow">http://seekingalpha.com/article/298781-3-contenders-to-be-the-first-profitable-stem-cell-company?source=from_friend</a> </p> http://biotechbistro.com/forum/topic/science-good-or-bad#post-244 Fri, 28 Oct 2011 01:32:36 +0000 williams_john 244@http://biotechbistro.com/forum/ <p>science invention brought lot of benefit for us..... but now a day . use it in negative way....<br /> So discuss your comments with detail here </p>